GHK-Cu

GHK is a fragment released from collagen during tissue injury, and it carries copper(II) with high affinity - the complex is the active species. Microarray work by Pickart and colleagues showed GHK-Cu resets expression of over 4000 human genes toward a younger profile, including upregulation of collagen I and III, elastin, decorin, and the antioxidant enzymes superoxide dismutase and metallothionein, alongside downregulation of several inflammatory and fibrotic pathways. It also stimulates angiogenesis by increasing VEGF and FGF-2, and it chelates iron, which is part of its antioxidant effect. Blood levels of GHK fall sharply with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60, which is the basis for the anti-aging framing. Topical evidence in humans is decent; injectable evidence in humans is essentially absent.

Targets: Copper transport and cellular copper delivery, Collagen I / III and elastin gene expression, Decorin, SOD and metallothionein, VEGF and FGF-2

• · Effective creams and serums sit around 1-3 percent GHK-Cu. This is the route with the best human evidence and effectively no systemic risk.
• · Anecdotal only. Injection is noticeably painful and often leaves a lasting red or brown mark at the site. Runs are kept short - typically 30 days - specifically because of copper accumulation concerns.

Work out your exact syringe units →

• very commonInjection-site pain, redness and residual brown or blue staining— The single most reported issue with injectable GHK-Cu; marks can persist for weeks.
• uncommonMetallic taste or nausea— A sign you are pushing the copper load; back off.
• uncommonSkin irritation or contact dermatitis with topicals— More common at concentrations above 3 percent.
• rareCopper accumulation with prolonged high-dose injection— Theoretical rather than documented at cosmetic doses, but it is the reason cycles are kept short.

• Wilson's disease or any condition of impaired copper excretion - injecting a copper complex here is directly dangerous.
• Known copper allergy or hypersensitivity.
• Active malignancy - GHK-Cu is pro-angiogenic.

• synergybpc-157 — Commonly paired for wound and post-surgical repair, combining matrix remodelling with angiogenesis.
• synergytb-500 — Used together for scar quality after injury.
• cautionTopical vitamin C or hydroxy acids — Low pH and strong reducing agents can destabilise the copper complex; separate them by application or time of day.
• cautionZinc supplementation — High-dose zinc and copper compete; long copper runs alongside heavy zinc dosing can push either mineral out of balance.

• · For extended injectable use, serum copper and ceruloplasmin are the sensible checks.
• · Topical use needs no monitoring beyond looking at your skin.

Freely available as a cosmetic ingredient worldwide. The injectable form is sold as a research chemical and is not approved for human injection anywhere. In April 2026 the FDA removed injectable GHK-Cu from the Category 2 bulk drug substances list, alongside BPC-157, TB-500 and KPV. Removal from Category 2 is not authorisation to compound - GHK-Cu was not among the peptides taken to the July 2026 Pharmacy Compounding Advisory Committee vote, so it has no affirmative 503A listing.

• Pickart & Margolina 2018, regenerative and protective actions of the GHK-Cu peptide, International Journal of Molecular Sciences (review)
• Pickart, Vasquez-Soltero & Margolina, GHK peptide and human gene expression (review) (review)
• Controlled facial cream studies of copper tripeptide-1 on skin density and fine lines (trial)

GHK is a fragment of collagen alpha-2(I) that is released when collagen is broken down, which makes it a genuine damage signal - the tissue is literally announcing its own injury in a form that switches on repair. It binds copper(II) with high affinity, and the complex, not the bare peptide, is the active species. Two mechanisms run in parallel. The first is copper delivery: GHK-Cu is an exchangeable copper carrier that hands copper to cells and to copper-dependent enzymes, including lysyl oxidase, which is the enzyme that cross-links collagen and elastin. That is a direct, unglamorous explanation for why skin treated with GHK-Cu gets firmer - you are supplying the cofactor for the cross-linking step. The second is transcriptional and much broader. Microarray work found GHK-Cu shifts expression of a very large number of human genes, with upregulation of collagen I and III, elastin, decorin and the glycosaminoglycan machinery, plus the antioxidant enzymes superoxide dismutase and metallothionein, and downregulation of a set of inflammatory and fibrotic programmes. It raises VEGF and FGF-2, which is the angiogenic arm, and it downregulates TGF-beta driven scarring, which is why the matrix it produces looks more like normal dermis and less like scar. A third, less-discussed action is iron chelation. GHK binds iron and reduces iron-catalysed lipid peroxidation, which contributes to the antioxidant effect and is relevant in wounds where free iron from lysed red cells is driving oxidative damage. The clinical shape of all this: topical GHK-Cu is slow, cumulative and works on matrix quality rather than on pigment, oil or turnover, which is why 8-12 weeks is the honest assessment window and why it stacks so naturally with retinoids that act on turnover instead. The age story - plasma GHK falling from roughly 200 ng/mL at twenty to about 80 ng/mL by sixty - comes from Pickart's own work and is the basis for the anti-aging framing. It is a correlation with age, not a demonstration that restoring it does anything systemically.

The injection-site reaction is the number one reason people stop, and it is not an allergy - it is a copper complex sitting in subcutaneous tissue. Pain during injection, a red or blue-brown mark afterward, and staining that can last weeks. Starting at 2 mg guarantees it. Starting at 500 mcg and stepping up gives you a chance to find out how you react before you have marked yourself. The second failure is treating the injectable route as though it has the topical route's evidence base. It does not. Topical GHK-Cu has repeated small controlled human studies. Subcutaneous GHK-Cu for systemic anti-aging has none at all - zero human trials - and it is the route where the copper load is real. That asymmetry is the single most important thing to understand about this compound. The third is running it continuously. Copper is excreted through bile at a limited rate. Thirty-day cycles with equal breaks exist for that reason, not as an arbitrary peptide convention. Metallic taste or nausea is your body telling you the load is too high; it is a stop signal, not a side effect to tolerate. The fourth is Wilson's disease and other copper-handling disorders. Most people with Wilson's are diagnosed young, but not all, and injecting a copper complex into someone who cannot excrete copper is directly dangerous rather than theoretically risky. The fifth is a formulation error: a serum that has gone from deep blue to pale or cloudy has lost the complex. Discard it. Colour is a free, real-time assay here and almost nobody uses it.

1. 500 mcgDays 1-4 (injectable only) — Start low specifically because the injection-site reaction is dose-related and genuinely unpleasant - pain, redness and a blue or brown mark that can persist for weeks. Starting at 2 mg is how people end up with a stain on their abdomen they did not consent to.
2. 1 mgDays 5-10 — Only step up if the site reaction from step 1 settled within a day. If it did not, this is your dose ceiling.
3. 2 mgDays 11-30 — The top of the commonly used band. Inject into abdominal fat, well away from the face, and rotate sites every time.
4. —After day 30 — Stop for at least as long as you ran. This is not peptide caution, it is metal caution - copper has a body burden and a biliary excretion bottleneck, and the reason cycles are short has nothing to do with the tripeptide.

• Copper(II) - the complex itself — GHK binds Cu(II) with an affinity comparable to that of albumin's copper site, which is what allows physiological exchange rather than sequestration

  Delivers exchangeable copper to cells and copper-dependent enzymes including lysyl oxidase, the collagen and elastin cross-linking enzyme.

• Collagen I and III, elastin, decorin and glycosaminoglycan gene expression — Transcriptional modulation; no receptor identified

  Increased dermal matrix synthesis. The main mechanism behind the measurable increase in skin density and firmness in topical trials.

• Superoxide dismutase and metallothionein — Transcriptional upregulation

  Antioxidant defence, plus metallothionein induction which is also part of how the body buffers a copper load.

• VEGF and FGF-2 — Transcriptional upregulation

  Angiogenesis and granulation tissue formation - the wound-healing arm, and also the reason it is a poor idea around known tumour.

• TGF-beta driven fibrotic signalling — Not characterised

  Downregulation, producing better-organised matrix and less hypertrophic scar.

• Free iron — Chelation; constants not stated here

  Reduced iron-catalysed lipid peroxidation, contributing to the antioxidant effect in wounds.

• Randomised controlled study of topical copper tripeptide complex on CO2 laser-resurfaced skin Investigator-initiated controlled trial · 2006

  Compared a copper tripeptide complex with standard post-laser care on re-epithelialisation and cosmetic outcome after facial CO2 laser resurfacing. One of the better-designed human uses of topical GHK-Cu in a genuine wound-healing setting rather than a cosmetic one.

Topical, days 1-14: nothing visible. Possibly mild irritation if the concentration is above 3 percent. Topical, weeks 4-8: the earliest honest window. Texture and hydration tend to move before anything measurable happens to lines. Topical, weeks 8-12: the assessment point used in the trials. Skin density and fine-line changes are judged here, ideally with standardised photographs rather than by mirror impression. Wounds, days to weeks: much faster, because you are accelerating an active healing process rather than remodelling quiescent tissue. The post-laser work looked at re-epithelialisation over days. Injectable: no timeline can be given honestly because there is no human trial. Anecdotal reports of systemic effects within a few weeks are exactly that.

Topically, the strongest pairing is with a retinoid, and the reason is mechanistic rather than habitual: the retinoid accelerates epidermal turnover while GHK-Cu builds dermal matrix, so they operate on different layers on different timescales. Use them at opposite ends of the day if irritation is an issue. Do not apply GHK-Cu in the same layer as L-ascorbic acid or a strong acid exfoliant. Low pH and strong reducing conditions destabilise the copper complex - if your blue serum goes colourless when mixed, you have just watched the active species fall apart. Morning acid, evening copper, or vice versa. With injectable BPC-157 or TB-500 for wound and post-surgical work, the combination is coherent: perfusion and cell migration from those, matrix quality and reduced scarring from this. With zinc supplementation, watch the ratio. High-dose zinc induces metallothionein in the gut and blocks copper absorption; a long copper run alongside 50 mg of zinc a day pushes both minerals around in ways that are hard to predict. With decapeptide-12 or any tyrosinase inhibitor there is a genuine theoretical conflict - copper is the cofactor for tyrosinase, so you are supplying the enzyme the other product is trying to block. Separate them or pick one.

Against tretinoin for facial skin: tretinoin has vastly more human evidence and a larger effect on photoaging, and it is also more irritating. GHK-Cu is the gentler, slower, matrix-directed option, and the two are complementary rather than competing. Against injectable GHK-Cu specifically: the topical route has the evidence, effectively no systemic risk and a fraction of the hassle. If you are choosing between them for skin, this is not a close call. Against BPC-157 and TB-500 for wounds: those act on blood supply and cell migration; GHK-Cu acts on the matrix that gets laid down. For scar quality after surgery or laser work, GHK-Cu is the better-matched tool and the one with actual human wound data. Against oral copper supplementation for the same purpose: not the same thing. Oral copper raises body copper without delivering the tripeptide signal, and the transcriptional effects are attributed to the complex rather than to copper alone. Against collagen peptides for skin: collagen peptides have larger randomised trials with modest effect sizes and no metal load. If you want one skin intervention with human evidence and no downside, that is the safer pick; GHK-Cu topically is the one with the more interesting mechanism.

$20–$90/month. Topical serums at 1-3 percent occupy the low end and are the route with the evidence. Injectable research vials at 50-100 mg run higher per cycle. Order-of-magnitude estimate, not price-checked in the preparation of this entry.

• ?No human pharmacokinetics for either route - no tmax, bioavailability, volume of distribution or clearance figure for GHK-Cu as administered.
• ?The gene-expression work underpinning the anti-aging claims comes overwhelmingly from one investigator and has not been independently replicated at scale.
• ?The plasma GHK decline with age (roughly 200 ng/mL at 20 falling to about 80 ng/mL at 60) is a correlation reported in that same body of work; there is no evidence that restoring it systemically does anything.
• ?There are zero human trials of subcutaneous GHK-Cu for any indication. The 1-2 mg daily band is entirely community convention.
• ?Copper accumulation at cosmetic injectable doses is a theoretical concern, not a documented one - but no study has looked, which is a different thing from a study finding nothing.
• ?Whether the copper or the peptide is responsible for which part of the transcriptional effect has not been cleanly separated.
• ?The Miller 2006 laser study's participant number and duration could not be confirmed from the abstract in this session.
• ?Cost figures are estimates and were not price-verified in this session.

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, Margolina A, International Journal of Molecular Sciences, 2018 · PMID 29986520

  The definitive review of the gene-expression work, the age-related decline in plasma GHK, and the collagen, elastin, decorin and antioxidant findings. Written by the discoverer, which is worth keeping in mind.

• Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Miller TR et al., Archives of Facial Plastic Surgery, 2006 · PMID 16847171

  A controlled human study in a real wound-healing context rather than a cosmetic one, which is the harder and more informative test.